Niagen Bioscience, Inc. current report, 13 February 2018

SEC Filing Summary: ChromaDex Corporation (8-K)

Business Context and Reporting Period

This Form 8-K was filed by ChromaDex Corporation on February 16, 2018, reporting an event that occurred on February 13, 2018. The registrant is incorporated in Delaware and operates from Irvine, California. The filing addresses a change in corporate governance regarding the Board of Directors.

Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current report regarding a specific corporate event and does not contain financial statements or performance metrics.

Material Changes

The material change reported is the departure of a director. Stephen Allen informed the Company that he does not intend to stand for reelection to the Board of Directors at the 2018 Annual Meeting of Stockholders. The Company explicitly stated that this decision is not the result of a disagreement with the Company on any matter relating to operations, policies, or practices.

Guidance, Outlook, and Risks

The filing contains no financial guidance, outlook, or management commentary regarding future performance. No specific risks or contingencies were disclosed in this document other than the standard governance change. There are no unusual items reported.

Key Facts for Investor Verification

  • Stephen Allen will not seek reelection to the Board of Directors at the 2018 Annual Meeting.
  • The departure is voluntary and not due to any disagreement with the Company.
  • The filing was signed by Frank L. Jaksch, Jr., Chief Executive Officer.
  • No financial data is included in this specific 8-K filing.